Whether it’s a virtual appointment or an in-person visit, it’s important to have open and honest conversations with your doctor about how well your current treatment plan is working. And preparing ahead of time can help make the discussion more productive. Use our Doctor Discussion
Guide to help track how you’re feeling, find helpful questions, and ensure you’re both speaking the same
language.
Moderate to SevereRheumatoid Arthritis
ActivePsoriatic Arthritis
Moderate to SevereUlcerative Colitis
Tracking Your Rheumatoid Arthritis Symptoms
In three simple steps, we’ll help you prepare for a more productive conversation with your doctor about how your rheumatoid arthritis (RA) symptoms may be impacting you and whether XELJANZ/XELJANZ XR could be an option for you.
Of course, you may have good days and bad days. But your doctor needs to know if symptoms of your moderate to severe RA are affecting your ability to perform common daily activities.
Select any task (and pick a color) to rate how difficult it is for you to
perform.
Easy
Medium
Hard/Unable
Getting Out Of Bed
Getting Dressed
Bathing
Grooming
Eating
Walking
Reaching
Gripping
Second Step
Step 2 of 3
Where Have You Noticed Any Symptoms?
If you’re experiencing RA symptoms that bother you or you notice symptoms in different parts of your body, talk to your doctor about your current treatment plan.
Select a symptom and mark an area of the body where you’ve been experiencing new joint pain, swelling, or both.
Joint pain
Joint swelling
Third Step
Step 3 of 3
What Are Your RA Symptoms?
Tracking your RA symptoms and how these can impact your ability to do simple daily tasks is important. Share this information with your doctor.
Check any symptoms you may be experiencing.
Fourth Step
All Done. Here’s Your Recap.
Now that you’ve recorded your recent rheumatoid arthritis symptoms, share this self-assessment with your doctor to help you discuss your symptom management and
treatment plan.
You’re all set. For more tools, tips, and support, sign up now.
This tracker is provided for educational purposes only and is not intended to replace discussions with a
healthcare provider. This is not intended to be used as a diagnostic tool. Decisions regarding patient care
must
be made with a healthcare provider, considering the unique characteristics of the patient.
This tracker is provided for educational purposes only and is not intended to replace discussions with a
healthcare provider. This is not intended to be used as a diagnostic tool. Decisions regarding patient care
must
be made with a healthcare provider, considering the unique characteristics of the patient.
Talking To Your Doctor
To start a meaningful conversation with your doctor, it's helpful to come prepared with important questions
about your treatment plan. Before your next appointment, consider the following questions and select ones to
help you and your healthcare provider discuss the risks and benefits of treatment with XELJANZ/XELJANZ XR for your moderate to severe RA.
You’re all set. For more tools, tips, and support, sign up now.
Speaking The Same Language
No matter where you are with your treatment, being able to clearly communicate your treatment goals,
expectations—and even frustrations—is crucial to having an honest conversation with your doctor. Before
your next appointment, use this glossary as a handy reference to help you and your doctor align on a
treatment plan you both believe in.
Articular Cartilage
A type of connective tissue that covers the surfaces of bones at the joints, providing cushioning and allowing the bones to slide or move against one another easily.
Joint Damage
Joint damage from rheumatoid arthritis is caused by destruction of bone and cartilage and can result in joint erosion and joint space narrowing. If untreated or undertreated, rheumatoid arthritis can lead to permanent joint damage. Certain treatments may help reduce further joint damage.
Bony Ankylosis
The fusing of bones together that can lead to reduced mobility.
Joint Inflammation
Swelling due to the body’s immune system response. In patients with moderate to severe rheumatoid arthritis, inflammation is believed to be the cause of joint pain and swelling.
Synovium
A thin membrane that surrounds the joints and produces synovial fluid, which lubricates the joints.
Fibrous Ankylosis
An abnormal connection between the bones in a joint that can impair movement and lead to stiffness.
Pannus
Granulation tissue that can be caused by joint inflammation. In rheumatoid arthritis, this tissue can invade and erode cartilage and bone.
In three simple steps, we’ll help you prepare for a more productive conversation with your doctor about how your psoriatic arthritis symptoms may be impacting you and whether XELJANZ/XELJANZ XR could be an option for you.
Is Psoriatic Arthritis Impacting Your Daily Activities?
Of course, you may have good days and bad days. But your doctor needs to know if symptoms of your active psoriatic arthritis are affecting your ability to perform common daily activities.
Select any task (and pick a color) to rate how difficult it is for you to
perform.
Easy
Medium
Hard/Unable
Getting Out Of Bed
Getting Dressed
Bathing
Grooming
Eating
Walking
Reaching
Gripping
Second Step
Step 2 of 3
Where Have You Noticed Any Symptoms?
If you’re experiencing psoriatic arthritis symptoms that bother you or you notice symptoms in different parts of your body, talk to your doctor about your current treatment plan.
Select a symptom and mark an area of the body where you’ve been experiencing new joint pain, swelling, or both.
Joint pain
Joint swelling
Third Step
Step 3 of 3
What Are Your Psoriatic Arthritis Symptoms?
Tracking your psoriatic arthritis symptoms and how these symptoms can impact your ability to do simple daily tasks is important. Share this information with your doctor.
Check any symptoms you may be experiencing.
Fourth Step
All Done. Here's Your Recap.
Now that you’ve recorded your recent psoriatic arthritis symptoms, share this self-assessment with your doctor to help you discuss your symptom management and treatment plan.
You’re all set. For more tools, tips, and support, sign up now.
This tracker is provided for educational purposes only and is not intended to replace discussions with a
healthcare provider. This is not intended to be used as a diagnostic tool. Decisions regarding patient care
must
be made with a healthcare provider, considering the unique characteristics of the patient.
This tracker is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. This is not intended to be used as a diagnostic tool. Decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.
Talking To Your Doctor
To start a meaningful conversation with your doctor, it's helpful to come prepared with important questions about your treatment plan. Before your next appointment, consider the following questions. Then select ones to help you and your healthcare provider discuss the risks and benefits of treatment with XELJANZ/XELJANZ XR for your active psoriatic arthritis.
You’re all set. For more tools, tips, and support, sign up now.
Speaking The Same Language
No matter where you are with your treatment, being able to clearly communicate your treatment goals, expectations—and even frustrations—is crucial to having an honest conversation with your doctor. Before your next appointment, use this glossary as a handy reference to help you and your doctor align on a treatment plan you both believe in.
Articular Cartilage
A type of connective tissue that covers the surfaces of bones at the joints, providing cushioning and allowing the bones to slide or move against one another easily.
Enthesitis
Inflammation where tendons and ligaments insert into bone—like the Achilles tendon.
Joint Inflammation
Swelling due to the body’s immune system response. In patients with active psoriatic arthritis, inflammation is believed to be the cause of symptoms in different areas of the body.
Bony Ankylosis
The fusing of bones together that can lead to reduced mobility.
Fibrous Ankylosis
An abnormal connection between the bones in a joint that can impair movement and lead to stiffness.
Pannus
Granulation tissue that can be caused by joint inflammation. In psoriatic arthritis, this tissue can invade and erode cartilage and bone.
Dactylitis
Inflammation of the fingers or toes that may reduce mobility and cause tenderness.
Joint Damage
Joint damage from psoriatic arthritis is caused by destruction of bone and cartilage and can result in joint erosion and joint space narrowing. If untreated or undertreated, psoriatic arthritis can lead to permanent joint damage. Certain treatments may help reduce further joint damage.
Synovium
A thin membrane that surrounds the joints and produces synovial fluid, which lubricates the joints.
Is Your Approach To Life With UC All That It Can Be?
Have you resigned yourself to the idea that life with UC may be as good as it’s going to get? We’ve created this quiz to help you take a fresh look at your approach and think about how you discuss your disease and treatment plan with your gastroenterologist (GI).
I feel confident planning and attending social commitments despite my ulcerative colitis.
I’m open and honest when I talk with my GI about my ulcerative colitis symptoms.
I regularly research information about ulcerative colitis.
I actively try to connect with other people living with ulcerative colitis.
I worry about the impact of ulcerative colitis on my life.
I look for different ways to increase my level of activity that may help relieve tension and reduce stress.
I’d consider working with a dietitian.
I’d be open to talking to a counselor about my emotional well-being.
Don’t Let Ulcerative Colitis Discourage You.
You answered “Me” to 0 questions.
Living with ulcerative colitis can be challenging. You might feel worn down, but don't give up. You have options to help manage the impact of your condition. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Don’t Let Ulcerative Colitis Discourage You.
You answered “Me” to 1 question.
Living with ulcerative colitis can be challenging. You might feel worn down, but don't give up. You have options to help manage the impact of your condition. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Don’t Let Ulcerative Colitis Discourage You.
You answered “Me” to 2 questions.
Living with ulcerative colitis can be challenging. You might feel worn down, but don't give up. You have options to help manage the impact of your condition. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Gaining Knowledge Is Power.
You answered “Me” to 3 questions.
An open minded approach can sometimes help in making informed decisions. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Gaining Knowledge Is Power.
You answered “Me” to 4 questions.
An open minded approach can sometimes help in making informed decisions. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Gaining Knowledge Is Power.
You answered “Me” to 5 questions.
An open minded approach can sometimes help in making informed decisions. Talk to your GI about your UC symptoms, your current treatment plan, and what options may be available for you.
You’re all set. For more tools, tips, and support, sign up now.
Stay Proactive & Engaged.
You answered “Me” to 6 questions.
It sounds like you try not to let ulcerative colitis stop you from imagining a positive future as you manage your condition with your healthcare team. Talk to your GI to see if there are options you haven’t considered to help you live a fuller life with UC.
You’re all set. For more tools, tips, and support, sign up now.
Stay Proactive & Engaged.
You answered “Me” to 7 questions.
It sounds like you try not to let ulcerative colitis stop you from imagining a positive future as you manage your condition with your healthcare team. Talk to your GI to see if there are options you haven’t considered to help you live a fuller life with UC.
You’re all set. For more tools, tips, and support, sign up now.
Stay Proactive & Engaged.
You answered “Me” to 8 questions.
It sounds like you try not to let ulcerative colitis stop you from imagining a positive future as you manage your condition with your healthcare team. Talk to your GI to see if there are options you haven’t considered to help you live a fuller life with UC.
You’re all set. For more tools, tips, and support, sign up now.
All content on this website is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
All content on this website is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Talking To Your Doctor
To start a meaningful conversation with your doctor, it's helpful to come prepared with important questions about your treatment plan. Before your next appointment, consider the following questions and select ones to help you and your healthcare provider discuss the risks and benefits of treatment with XELJANZ/XELJANZ XR for your moderate to severe ulcerative colitis (UC).
You’re all set. For more tools, tips, and support, sign up now.
Speaking The Same Language
Before you speak with your doctor, it can be helpful to review some medical terms and definitions you may need when discussing your ulcerative colitis. Use this glossary tool as a handy reference as you prepare for your next appointment.
Anemia
It’s a condition where the body has fewer red blood cells than normal, which may result in fatigue, shortness of breath, dizziness, headache, and irregular heartbeat.
Colonoscopy
A colonoscopy is an exam where your gastroenterologist uses a thin, flexible, lighted tube with an attached camera to view your colon, and possibly to take tissue samples.
Gastrointestinal Bleeding
Bleeding in any part of the gastrointestinal tract.
Mucosa
Mucosa is the innermost layer of the GI tract. Mucosal surfaces are areas in the body where absorption happens. The inflammation of ulcerative colitis is typically limited to the colonic mucosa.
Remission
Remission is a time when your UC symptoms are under control or you are experiencing few to no symptoms.
Bowel Urgency
Strong urge to have a bowel movement.
Flare
An ulcerative colitis flare, or flare-up, is the return of UC symptoms after a period of remission. Flares can involve diarrhea, abdominal pain and cramping, rectal pain and bleeding, fatigue, and urgent bowel movements.
Gastrointestinal Tract (GI Tract)
The large, muscular tube that extends from the mouth to the anus, where the movement of muscles and the release of hormones and enzymes help with the digestion of food. Also called the digestive tract.
Rectal Bleeding
Rectal bleeding can refer to any blood that passes from your anus.
Stool Frequency
The normal length of time between bowel movements ranges widely depending on the person, and may also be affected by the severity of an underlying medical condition.
Colon
The colon, or large bowel, is a tube-like organ connected to the small intestine at one end and the anus at the other. The colon removes water, and some nutrients and electrolytes, from partially digested food.
Flexible Sigmoidoscopy
This is a procedure where your gastroenterologist uses a slender, flexible, lighted tube to examine the rectum and the last portion of your colon. It’s sometimes performed in place of a full colonoscopy.
Inflammation
Irritation or swelling. In UC, the symptoms a person experiences can vary, depending on how severe the inflammation is and where it occurs in the intestine.
Rectum
The last several inches of the large intestine closest to the anus.
Tenesmus
Tenesmus is the feeling of needing to pass stool even when the bowels are empty.
Ulcer
A sore on the skin’s surface or on the stomach or intestinal lining.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated
Active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with active polyarticular juvenile arthritis.
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular juvenile arthritis.
It is not known if XELJANZ XR is safe and effective in children.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active » Read More
Important Safety Information
The safety information below applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing is noted.
Serious Infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ.
Before and after starting XELJANZ, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chills
Cough
Blood in phlegm
Warm, red, or painful skin or sores on your body
Burning when you urinate
Urinating more often than normal
Muscle aches
Shortness of breath
Weight loss
Diarrhea or stomach pain
Feeling very tired
Increased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of XELJANZ/XELJANZ XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is XELJANZ 5 mg twice daily or XELJANZ XR 11 mg one time each day.
Cancer. XELJANZ/XELJANZ XR may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose. People taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of XELJANZ/XELJANZ XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not receive XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
tocilizumab (Actemra®)
etanercept (Enbrel®)
adalimumab (Humira®)
infliximab (Remicade®)
rituximab (Rituxan®)
abatacept (Orencia®)
anakinra (Kineret®)
certolizumab (Cimzia®)
golimumab (Simponi®)
ustekinumab (Stelara®)
secukinumab (Cosentyx®)
vedolizumab (Entyvio®)
sarilumab (Kevzara®)
azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular juvenile idiopathic arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.
Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.
You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated
Active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with active polyarticular juvenile arthritis.
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular juvenile arthritis.
It is not known if XELJANZ XR is safe and effective in children.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated...Read More
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active » Read More
Important Safety Information
The safety information below applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing is noted.
Serious Infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ.
Before and after starting XELJANZ, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chills
Cough
Blood in phlegm
Warm, red, or painful skin or sores on your body
Burning when you urinate
Urinating more often than normal
Muscle aches
Shortness of breath
Weight loss
Diarrhea or stomach pain
Feeling very tired
Increased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of XELJANZ/XELJANZ XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is XELJANZ 5 mg twice daily or XELJANZ XR 11 mg one time each day.
Cancer. XELJANZ/XELJANZ XR may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose. People taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of XELJANZ/XELJANZ XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not receive XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
tocilizumab (Actemra®)
etanercept (Enbrel®)
adalimumab (Humira®)
infliximab (Remicade®)
rituximab (Rituxan®)
abatacept (Orencia®)
anakinra (Kineret®)
certolizumab (Cimzia®)
golimumab (Simponi®)
ustekinumab (Stelara®)
secukinumab (Cosentyx®)
vedolizumab (Entyvio®)
sarilumab (Kevzara®)
azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular juvenile idiopathic arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.
Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.
You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.
If you have questions, concerns, or comments, please call our XELJANZ Information Center toll-free at 1-844-935-5269 Monday through Friday, 8:00 AM–8:00 PM ET.
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report adverse events or product quality complaints related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088. By clicking on this link, you will be leaving XELJANZ.com. This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content and services of this site.
You Are Now Leaving This Pfizer Site
Links to other sites are provided as a convenience to the visitor. Pfizer accepts no responsibility for the content of linked sites.
PFIZER PATIENT ASSISTANCE PROGRAM ELIGIBILITY CRITERIA
The Pfizer Patient Assistance Program is not health insurance and is available for eligible uninsured/underinsured patients only.
Offer is only available to patients who meet financial and other criteria.
This offer does not require, nor will it be made contingent on, purchase requirements of any kind.
No claim for reimbursement or credit for any costs associated with the medicine(s) may be submitted to any prescription insurance provider or payer, including Medicare Part D plans.
Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification.
Offer good only in the US and Puerto Rico.
Patient must be a resident of the US or Puerto Rico.
Prescription must be provided by a healthcare provider licensed in the US or Puerto Rico.
Patient must be treated in the outpatient setting of care.
Additional eligibility criteria may apply. Contact XELSOURCE for details.
INTERIM CARE Rx PROGRAM TERMS & CONDITIONS
Interim Care Rx is not health insurance and is available for eligible, commercially insured patients only.
Offer is only available to patients who have been diagnosed with an FDA-approved indication for XELJANZ.
No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer.
Not available to patients covered under government plans such as Medicaid, Medicare or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio, or Rhode Island.
Available in 30-day supply. Refills are subject to limitations.
Interim Care Rx offer does not require, nor will be made contingent on, purchase requirements of any kind.
Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification.
Interim Care Rx can only be dispensed by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process.
Offer good only in the U.S. and Puerto Rico.
Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico.
Continued eligibility for the program requires the submission of two appeals within 180 days of
enrollment. After 12 months of program enrollment an updated prescription and benefits investigation is
required to confirm continued eligibility.
The Interim Care Rx Program is applicable to all XELJANZ formulations.
Additional eligibility criteria may apply. Contact XELSOURCE for details.
VOUCHER TERMS AND CONDITIONS
By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the terms & conditions described below:
You will receive a one-time, 30-day supply of XELJANZ.
Only new patients may use this voucher. By redeeming this voucher, you certify that you are not currently using XELJANZ.
An original voucher and a valid prescription must be presented to the pharmacy.
The voucher will be accepted only at participating pharmacies.*
You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
This voucher is not valid where prohibited by law.
This voucher cannot be combined with any other savings, free trial or similar offer for the specified prescription. This voucher should not be combined with samples for the specified prescription.
This free trial voucher is not health insurance. This free trial voucher is not intended to address delays or gaps in health insurance coverage for the specified prescription.
Offer good only in the U.S. and Puerto Rico.
No purchase is necessary.
Patients have no obligation to continue to use XELJANZ.
Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
The voucher is applicable to all XELJANZ formulations.
This voucher expires 12/31/2022.
*MA residents may select their pharmacy. Otherwise, this free trial will be supplied through XELSOURCE.
CO-PAY CARD TERMS AND CONDITIONS
By using the XELJANZ Co-pay Savings Card (the “Card”), you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
Patients are not eligible to use the Card if they are enrolled in a state- or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
Patient must have private insurance. Offer is not valid for cash-paying patients.
You will receive a maximum benefit of $15,000 per calendar year, which is defined by the date of enrollment through December 31st of the enrollment year, and may pay as little as $0 per month co-pay. After a maximum of $15,000, you will be responsible for paying the remaining monthly out-of-pocket costs.
This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
You must deduct the value of this Card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
You are responsible for reporting use of the Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required. You should not use the Card if your insurer or health plan prohibits use of manufacturer Cards.
The Card is not valid where prohibited by law.
The Card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
The Card will be accepted only at participating pharmacies.
If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
The Card is not health insurance.
Offer good only in the U.S. and Puerto Rico.
The Card is limited to 1 per person during this offering period and is not transferable.
The Card may not be redeemed more than once per 30 days per patient.
No other purchase is necessary.
Data related to your redemption of the Card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Card redemptions and will not identify you.
Pfizer reserves the right to rescind, revoke, or amend the program without notice.
The Card is applicable to all XELJANZ formulations.
Card and Program expires 12/31/2022.
XSAVINGS MOBILE TEXT PROGRAM TERMS & CONDITIONS
User texts "XPROGRAM" to short code 50336.
Text HELP for help, STOP to opt out.
Patients may receive up to 10 messages per month.
Message and data rates may apply.
By opting into the XSAVINGS mobile texting program (Program), you consent to receive up to 10 text messages and/or push notifications from Pfizer Inc. Such messages may be marketing or non-marketing messages and may include co-pay related information, fill confirmation, website information, etc. Messages may be delayed or undelivered for various factors. TrialCard, carriers (including, but not limited to, T-Mobile) and any service providers utilized by TrialCard to send messages are not liable for delayed or undelivered messages.
To stop receiving text messages, text STOP to 50336. DOING SO WILL ONLY OPT YOU OUT OF THIS PROGRAM; you will remain opted in to any other Pfizer Inc text message program(s) into which you opted separately.
To request more information or to obtain help, text HELP to 50336. You can also call customer service at 1-844-935-5269.
You represent that you are the account holder for the mobile telephone number(s) that you provide to opt into the Program. You are responsible for notifying Pfizer Inc immediately if you change your mobile telephone number. You may notify Pfizer Inc of a number change by calling 1-844-935-5269.
Message and data rates may apply to each text message sent or received in connection with the texting program, as provided in your mobile telephone service rate plan (please contact your mobile telephone carrier for pricing plans). Applicable roaming charges may apply. Charges are both billed and payable to your mobile service provider or deducted from your prepaid account. Pfizer Inc does not impose a separate fee for sending text messages.
Data obtained from you in connection with this Program may include your telephone number, your carrier's name, and details of the message (date, time, and content). Pfizer Inc may use this information to contact you and to provide the services you request.
For information on data collection and use, please read our full corporate Privacy Policy, which is incorporated by reference into these Terms.
Pfizer Inc will not be liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator.
This Program is available only on these US participating mobile carriers: Verizon Wireless, Sprint, Boost Mobile, T-Mobile, AT&T, Atlantic Tele-Network International (ATNI), Alaska Communications Systems (ACS), ASTAC, Bandwidth.com (includes Republic Wireless), Blue Wireless, Bluegrass Cellular, Breakaway Wireless, Brightlink, C Spire Wireless (aka Cellular South), Carolina West Wireless, CellCom, Cellone Nation, Cellular One of N.E. Arizona, Chariton Valley Cellular, Chat Mobility, Copper Valley Telecom, Cordova Wireless, Cross Wireless, CTC, Custer Telephone, East Kentucky Network (Appalachian Wireless), Enflick, GCI Communications, Google Voice, Illinois Valley Cellular, Inland Cellular, Inteliquent, iWireless, Leaco Rural Telephone Cooperative, Limitless Mobile, Mid-Rivers Communications, MobileNation/SI Wireless, MTA Wireless/Matanuska Kenai, Nemont CDMA, Nemont US UMTS, NewCore Wireless, Nex-Tech Wireless, NNTC Wireless, Northwest Missouri Cellular, Pine Belt Wireless, Pine Cellular, Pioneer Cellular, PTCI, Shelcomm, Silver Star PCS, Snake River PCS, SouthernLINC, SouthernLINC LTE, SRT, STRATA Networks, Standing Rock (SRTI), Thumb Cellular, Triangle Wireless, Union Wireless, U.S. Cellular, United Wireless, Viaero Wireless, Virgin Mobile, West Central Wireless.
You agree to indemnify Pfizer Inc and any third parties texting on its behalf in full for all claims, expenses, and damages related to or caused, in whole or in part, by your failure to immediately notify us if you change your telephone number, including but not limited to all claims, expenses, and damages related to or arising under the Telephone Consumer Protection Act.
Pfizer Inc may immediately suspend or terminate your participation in the Program if it believes you are in breach of these SMS Terms and Conditions. Your participation in this Program is also subject to termination in the event that your mobile telephone service terminates or lapses. Pfizer Inc reserves the right to modify or discontinue, temporarily or permanently, all or any part of the Program, with or without notice.
Pfizer Inc may revise, modify, or amend these SMS Terms and Conditions at any time. Any such revision, modification, or amendment shall take effect when it is posted to Pfizer Inc's website. You agree to review these SMS Terms and Conditions periodically to ensure that you are aware of any changes. Your continued consent to receive text messages will indicate your acceptance of those changes.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
Moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated
Active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with active polyarticular juvenile arthritis.
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular juvenile arthritis.
It is not known if XELJANZ XR is safe and effective in children.
Important Safety Information
The safety information below applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing is noted.
Serious Infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ.
Before and after starting XELJANZ, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chills
Cough
Blood in phlegm
Warm, red, or painful skin or sores on your body
Burning when you urinate
Urinating more often than normal
Muscle aches
Shortness of breath
Weight loss
Diarrhea or stomach pain
Feeling very tired
Increased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of XELJANZ/XELJANZ XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is XELJANZ 5 mg twice daily or XELJANZ XR 11 mg one time each day.
Cancer. XELJANZ/XELJANZ XR may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose. People taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of XELJANZ/XELJANZ XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not receive XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
tocilizumab (Actemra®)
etanercept (Enbrel®)
adalimumab (Humira®)
infliximab (Remicade®)
rituximab (Rituxan®)
abatacept (Orencia®)
anakinra (Kineret®)
certolizumab (Cimzia®)
golimumab (Simponi®)
ustekinumab (Stelara®)
secukinumab (Cosentyx®)
vedolizumab (Entyvio®)
sarilumab (Kevzara®)
azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular juvenile idiopathic arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.
Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.
You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.
